Emerging treatment for ALK-positive lung cancer

Janaki N. Sharma, Vipul Pareek, Huijie Liu, Haiying Cheng

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

ABSTRACT: Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of targetable genetic alterations, including the ALK fusion oncogene. Areascovered: Three drugs have been approved for clinical use in ALK-positive patients – crizotinib, ceritinib and alectinib. Unfortunately, treatment resistance inevitably develops. Several mechanisms of acquired resistance are reported. In this review, we will discuss emerging treatment options in ALK-positive advanced NSCLC and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy. Expertopinion: Tremendous advances have been made in the treatment of ALK-positive lung cancers, but management hurdles still exist, including universal development of resistance to ALK inhibitors and limited CNS activity. Given that specific treatment strategies target distinct patterns of resistance, re-biopsy at the time of progression appears necessary to optimize management. However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalExpert Opinion on Emerging Drugs
Volume21
Issue number2
DOIs
StatePublished - Apr 2 2016

Fingerprint

Lung Neoplasms
Non-Small Cell Lung Carcinoma
Oncogene Fusion
Biopsy
Therapeutics
Immunotherapy
Drug Therapy
Pharmaceutical Preparations

Keywords

  • ALK oncogene
  • Non-small cell lung cancer
  • resistance mechanisms
  • targeted therapy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging treatment for ALK-positive lung cancer. / Sharma, Janaki N.; Pareek, Vipul; Liu, Huijie; Cheng, Haiying.

In: Expert Opinion on Emerging Drugs, Vol. 21, No. 2, 02.04.2016, p. 147-155.

Research output: Contribution to journalReview article

Sharma, Janaki N. ; Pareek, Vipul ; Liu, Huijie ; Cheng, Haiying. / Emerging treatment for ALK-positive lung cancer. In: Expert Opinion on Emerging Drugs. 2016 ; Vol. 21, No. 2. pp. 147-155.
@article{d87132aa8e3f4deeab8fdc0abcc48289,
title = "Emerging treatment for ALK-positive lung cancer",
abstract = "ABSTRACT: Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of targetable genetic alterations, including the ALK fusion oncogene. Areascovered: Three drugs have been approved for clinical use in ALK-positive patients – crizotinib, ceritinib and alectinib. Unfortunately, treatment resistance inevitably develops. Several mechanisms of acquired resistance are reported. In this review, we will discuss emerging treatment options in ALK-positive advanced NSCLC and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy. Expertopinion: Tremendous advances have been made in the treatment of ALK-positive lung cancers, but management hurdles still exist, including universal development of resistance to ALK inhibitors and limited CNS activity. Given that specific treatment strategies target distinct patterns of resistance, re-biopsy at the time of progression appears necessary to optimize management. However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.",
keywords = "ALK oncogene, Non-small cell lung cancer, resistance mechanisms, targeted therapy, tyrosine kinase inhibitors",
author = "Sharma, {Janaki N.} and Vipul Pareek and Huijie Liu and Haiying Cheng",
year = "2016",
month = "4",
day = "2",
doi = "10.1080/14728214.2016.1183642",
language = "English (US)",
volume = "21",
pages = "147--155",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Emerging treatment for ALK-positive lung cancer

AU - Sharma, Janaki N.

AU - Pareek, Vipul

AU - Liu, Huijie

AU - Cheng, Haiying

PY - 2016/4/2

Y1 - 2016/4/2

N2 - ABSTRACT: Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of targetable genetic alterations, including the ALK fusion oncogene. Areascovered: Three drugs have been approved for clinical use in ALK-positive patients – crizotinib, ceritinib and alectinib. Unfortunately, treatment resistance inevitably develops. Several mechanisms of acquired resistance are reported. In this review, we will discuss emerging treatment options in ALK-positive advanced NSCLC and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy. Expertopinion: Tremendous advances have been made in the treatment of ALK-positive lung cancers, but management hurdles still exist, including universal development of resistance to ALK inhibitors and limited CNS activity. Given that specific treatment strategies target distinct patterns of resistance, re-biopsy at the time of progression appears necessary to optimize management. However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.

AB - ABSTRACT: Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the discovery of targetable genetic alterations, including the ALK fusion oncogene. Areascovered: Three drugs have been approved for clinical use in ALK-positive patients – crizotinib, ceritinib and alectinib. Unfortunately, treatment resistance inevitably develops. Several mechanisms of acquired resistance are reported. In this review, we will discuss emerging treatment options in ALK-positive advanced NSCLC and strategies to overcome resistance mechanisms, including newer generation of ALK inhibitors, Hsp90 inhibitors and immunotherapy. Expertopinion: Tremendous advances have been made in the treatment of ALK-positive lung cancers, but management hurdles still exist, including universal development of resistance to ALK inhibitors and limited CNS activity. Given that specific treatment strategies target distinct patterns of resistance, re-biopsy at the time of progression appears necessary to optimize management. However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.

KW - ALK oncogene

KW - Non-small cell lung cancer

KW - resistance mechanisms

KW - targeted therapy

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84975259868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975259868&partnerID=8YFLogxK

U2 - 10.1080/14728214.2016.1183642

DO - 10.1080/14728214.2016.1183642

M3 - Review article

C2 - 27122312

AN - SCOPUS:84975259868

VL - 21

SP - 147

EP - 155

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -